Drug Trial Radar · NCT05806164
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
432
Planned (sponsor's estimate)
Start
Jun 6, 2023
Primary completion
Aug 30, 2026
Study completion Aug 1, 2030
Sponsor
- Lead sponsor
- Women and Infants Hospital of Rhode IslandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of New Mexico; University of Alabama at Birmingham; University of California, San Diego; Howard University; Brown University; Patient-Centered Outcomes Research Institute
- First posted
- Apr 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity. The study will also have a long-term follow-up component (prospective cohort) including 346 participants from the parent trial to describe treatment continuation, treatment efficacy, patient direct costs and other secondary outcomes up to 5 years after treatment.
Conditions
- Urgency Urinary Incontinence
Interventions
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]Drug
The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
OnabotulinumtoxinA 100 UNT [Botox]Drug
OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in score Overactive Bladder Questionnaire-Symptom Bother Scale (OAB-q-SS) at 3 monthsTime frame: Baseline until 3 months
- Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General Questionnaire (FACIT-TS-G) at 3 monthsTime frame: 3 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California, San Diego
San Diego, California
Howard University
Washington D.C., District of Columbia
University of New Mexico
Albuquerque, New Mexico
Women & Infants Hospital of Rhode Island
Providence, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.